全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Optimal management of bone metastases in breast cancer patients

DOI: http://dx.doi.org/10.2147/BCTT.S6655

Keywords: breast cancer, bone metastases, bisphosphonates, denosumab, biomarkers, optimal management

Full-Text   Cite this paper   Add to My Lib

Abstract:

imal management of bone metastases in breast cancer patients Review (4878) Total Article Views Authors: Wong MH, Pavlakis N Published Date May 2011 Volume 2011:3 Pages 35 - 60 DOI: http://dx.doi.org/10.2147/BCTT.S6655 MH Wong, N Pavlakis Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia Abstract: Bone metastasis in breast cancer is a significant clinical problem. It not only indicates incurable disease with a guarded prognosis, but is also associated with skeletal-related morbidities including bone pain, pathological fractures, spinal cord compression, and hypercalcemia. In recent years, the mechanism of bone metastasis has been further elucidated. Bone metastasis involves a vicious cycle of close interaction between the tumor and the bone microenvironment. In patients with bone metastases, the goal of management is to prevent further skeletal-related events, manage complications, reduce bone pain, and improve quality of life. Bisphosphonates are a proven therapy for the above indications. Recently, a drug of a different class, the RANK ligand antibody, denosumab, has been shown to reduce skeletal-related events more than the bisphosphonate, zoledronic acid. Other strategies of clinical value may include surgery, radiotherapy, radiopharmaceuticals, and, of course, effective systemic therapy. In early breast cancer, bisphosphonates may have an antitumor effect and prevent both bone and non-bone metastases. Whilst two important Phase III trials with conflicting results have led to controversy in this topic, final results from these and other key Phase III trials must still be awaited before a firm conclusion can be drawn about the use of bisphosphonates in this setting. Advances in bone markers, predictive biomarkers, multi-imaging modalities, and the introduction of novel agents have ushered in a new era of proactive management for bone metastases in breast cancer.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133